Transcriptomic Characterization of Postmolar Gestational Choriocarcinoma.

choriocarcinoma gestational trophoblastic disease gestational trophoblastic neoplasia hydatidiform mole placenta transforming growth factor beta trophoblast

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
14 Oct 2021
Historique:
received: 31 08 2021
revised: 01 10 2021
accepted: 08 10 2021
entrez: 23 10 2021
pubmed: 24 10 2021
medline: 24 10 2021
Statut: epublish

Résumé

The human placenta shares properties with solid tumors, such as rapid growth, tissue invasion, cell migration, angiogenesis, and immune evasion. However, the mechanisms that drive the evolution from premalignant proliferative placental diseases-called hydatidiform moles-to their malignant counterparts, gestational choriocarcinoma, as well as the factors underlying the increased aggressiveness of choriocarcinoma arising after term delivery compared to those developing from hydatidiform moles, are unknown. Using a 730-gene panel covering 13 cancer-associated canonical pathways, we compared the transcriptomic profiles of complete moles to those of postmolar choriocarcinoma samples and those of postmolar to post-term delivery choriocarcinoma. We identified 33 genes differentially expressed between complete moles and postmolar choriocarcinoma, which revealed TGF-β pathway dysregulation. We found the strong expression of SALL4, an upstream regulator of TGF-β, in postmolar choriocarcinoma, compared to moles, in which its expression was almost null. Finally, there were no differentially expressed genes between postmolar and post-term delivery choriocarcinoma samples. To conclude, the TGF-β pathway appears to be a crucial step in the progression of placental malignancies. Further studies should investigate the value of TGF- β family members as biomarkers and new therapeutic targets.

Identifiants

pubmed: 34680590
pii: biomedicines9101474
doi: 10.3390/biomedicines9101474
pmc: PMC8533618
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Cancer. 2017 Jul 5;8(11):2033-2041
pubmed: 28819404
Exp Cell Res. 1994 Sep;214(1):93-9
pubmed: 8082752
Eur J Cancer. 2015 Sep;51(13):1725-31
pubmed: 26092638
Open Biol. 2018 Jun;8(6):
pubmed: 29950452
J Obstet Gynaecol India. 2014 Dec;64(Suppl 1):29-31
pubmed: 25404801
J Transl Med. 2018 Jul 9;16(1):191
pubmed: 29986714
Br J Cancer. 2006 Nov 6;95(9):1145-7
pubmed: 17031399
Cancer Manag Res. 2018 Oct 10;10:4459-4470
pubmed: 30349378
Int J Gynaecol Obstet. 2002 Jun;77(3):285-7
pubmed: 12065144
Gynecol Oncol. 2020 Sep;158(3):785-793
pubmed: 32513563
BJOG. 2020 Aug;127(9):1102-1107
pubmed: 32146729
Am J Obstet Gynecol. 2021 Apr;224(4):372.e1-372.e30
pubmed: 33031755
Best Pract Res Clin Obstet Gynaecol. 2021 Jul;74:29-41
pubmed: 33685819
Histol Histopathol. 2007 Mar;22(3):227-34
pubmed: 17163397
Clin Ther. 2021 Feb;43(2):246-264
pubmed: 33446335
Am J Obstet Gynecol. 2016 Mar;214(3):390.e1-8
pubmed: 26433171
Signal Transduct Target Ther. 2020 Jun 30;5(1):110
pubmed: 32606334
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):
pubmed: 28246180
Cancers (Basel). 2021 Jun 15;13(12):
pubmed: 34203890
J Gynecol Obstet Biol Reprod (Paris). 2016 Jun;45(6):559-62
pubmed: 26323857
Hum Pathol. 2016 Aug;54:121-6
pubmed: 27068524
J Biochem Mol Toxicol. 2019 Mar;33(3):e22262
pubmed: 30431698
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1097-101
pubmed: 18021220
Mol Cancer. 2018 Dec 20;17(1):176
pubmed: 30572883
Oncotarget. 2016 Nov 22;7(47):78206-78218
pubmed: 27661009
Nature. 2021 Apr;592(7852):80-85
pubmed: 33692543
Am J Hum Genet. 2018 Nov 1;103(5):740-751
pubmed: 30388401

Auteurs

Constance Collet (C)

Institut National de la Santé et de la Recherche Médicale U1292, Biologie et Biotechnologie pour la Santé, 38043 Grenoble, France.
Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Interdisciplinary Research Institute of Grenoble, CEDEX, 38054 Grenoble, France.
Service Obstétrique, Centre Hospitalo-Universitaire Grenoble Alpes, University Grenoble-Alpes, CS 10217, CEDEX 9, 38043 Grenoble, France.

Jonathan Lopez (J)

Department of Biochemistry and Molecular Biology, Plateforme de Recherche de Transfert en Oncologie, University of Lyon 1, Hospices Civils de Lyon, University Hospital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.
Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Faculté de Médecine Lyon Est, 69008 Lyon, France.

Christophe Battail (C)

Institut National de la Santé et de la Recherche Médicale U1292, Biologie et Biotechnologie pour la Santé, 38043 Grenoble, France.
Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Interdisciplinary Research Institute of Grenoble, CEDEX, 38054 Grenoble, France.
Service Obstétrique, Centre Hospitalo-Universitaire Grenoble Alpes, University Grenoble-Alpes, CS 10217, CEDEX 9, 38043 Grenoble, France.

Fabienne Allias (F)

Department of Pathology, University Hospital Lyon, Sud University of Lyon 1, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.
French Center for Trophoblastic Diseases, University Hospital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.

Mojgan Devouassoux-Shisheboran (M)

Department of Pathology, University Hospital Lyon, Sud University of Lyon 1, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.
French Center for Trophoblastic Diseases, University Hospital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.

Sophie Patrier (S)

French Center for Trophoblastic Diseases, University Hospital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.
Department of Pathology, University Hospital of Rouen, CEDEX, 76031 Rouen, France.

Nicolas Lemaitre (N)

Institut National de la Santé et de la Recherche Médicale U1292, Biologie et Biotechnologie pour la Santé, 38043 Grenoble, France.
Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Interdisciplinary Research Institute of Grenoble, CEDEX, 38054 Grenoble, France.
Service Obstétrique, Centre Hospitalo-Universitaire Grenoble Alpes, University Grenoble-Alpes, CS 10217, CEDEX 9, 38043 Grenoble, France.

Touria Hajri (T)

French Center for Trophoblastic Diseases, University Hospital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.

Jérôme Massardier (J)

French Center for Trophoblastic Diseases, University Hospital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.
Department of Obstetrics and Gynecology, University Hospital Femme Mere Enfant, University of Lyon 1, 51, Boulevard Pinel, 69500 Bron, France.

Benoit You (B)

French Center for Trophoblastic Diseases, University Hospital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.
Investigational Center for Treatments in Oncology and Hematology of Lyon (CITOHL), Medical Oncology Department, University of Lyon 1, Hospices Civils de Lyon, University Hospital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.

François Mallet (F)

Joint Research Unit Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud Hospital, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.
Medical Diagnostic Discovery Department (MD3), bioMérieux S.A., 69280 Marcy l'Etoile, France.
Joint Research Unit Hospices Civils de Lyon-bioMérieux, EA 7426 Patho-Physiology of Injury-Induced Immunosuppression, PI3, Claude Bernard Lyon 1 University, Edouard Herriot Hospital, 69437 Lyon, France.

François Golfier (F)

French Center for Trophoblastic Diseases, University Hospital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.
Department of Gynecological Surgery and Oncology, Hospices Civils de Lyon, University Hospital Lyon Sud, University of Lyon 1, Obstetrics, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.

Nadia Alfaidy (N)

Institut National de la Santé et de la Recherche Médicale U1292, Biologie et Biotechnologie pour la Santé, 38043 Grenoble, France.
Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Interdisciplinary Research Institute of Grenoble, CEDEX, 38054 Grenoble, France.
Service Obstétrique, Centre Hospitalo-Universitaire Grenoble Alpes, University Grenoble-Alpes, CS 10217, CEDEX 9, 38043 Grenoble, France.

Pierre-Adrien Bolze (PA)

French Center for Trophoblastic Diseases, University Hospital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.
Department of Gynecological Surgery and Oncology, Hospices Civils de Lyon, University Hospital Lyon Sud, University of Lyon 1, Obstetrics, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite, France.

Classifications MeSH